Early-pregnancy @entity413 screening for XXXX .

@entity1 @entity413 @entity6
OBJECTIVE: To determine the accuracy of the 50-g, one-hour @entity413 screening test administered at 16 weeks of pregnancy for identifying @entity1 with @entity6 . STUDY DESIGN: Two hundred fifty-five @entity1 underwent 50-g, one-hour @entity413 screening tests at 16 weeks of pregnancy. Those with results > or = 135 mg/dL underwent 100-g, three-hour @entity413 tolerance tests. All @entity1 without diagnoses of gestational @entity6 during the second trimester of pregnancy underwent standard third-trimester @entity413 testing. RESULTS: @entity6 was diagnosed in 25 @entity1 . @entity413 screening tests administered at 16 weeks of pregnancy identified 96% (24) of these @entity1 . @entity1 with 16-week @entity413 screening test results > or = 135 mg/dL had a 55% risk of developing @entity6 during pregnancy, while the risk was 0.6% for @entity1 with 16-week test results < or = 110 mg/dL. @entity1 with 16-week @entity413 screening test results in the intermediate range, 111-134 mg/dL, had a 4.8% risk of developing @entity6 during pregnancy. CONCLUSION: @entity413 screening at 16 weeks of pregnancy is a useful alternative to third-trimester screening for gestational @entity6 . The negative predictive value of screening test results < or = 110 mg/dL is 99.4%. The positive predictive value for screening test results > or = 135 mg/dL is 55%. This latter finding is superior to the 8.6-22% found during the third-trimester.
